Meningococcal Vaccines Market Analysis

Meningococcal Vaccines Market Analysis

To get key market trends

  Download Free Sample

Based on the vaccines type, the meningococcal vaccines market is segmented into polysaccharide, conjugate, combination, and other vaccine types. The conjugate vaccines segment held largest market share of 51.1% in 2022. These vaccines offer advantages in terms of efficacy, and the breadth of protection they provide against multiple serogroups of Neisseria meningitidis. By addressing multiple serogroups in a single vaccine formulation, conjugate vaccines offer comprehensive protection and eliminate the need for separate vaccinations against individual serogroups. They utilize a carrier protein to link the polysaccharide antigen of the bacterial capsule to a component that stimulates a robust immune response. This innovative approach enhances the immune system's recognition of the antigen, resulting in higher levels of protective antibodies. Moreover, they are effective in preventing disease both at the individual level and in outbreak situations. During outbreaks, their ability to interrupt disease transmission can be critical in controlling the spread of the infection. Therefore, the intricate and specialized demands of conjugate vaccines contribute to expand the global market growth.
 

Based on the brand, the global meningococcal vaccines market is classified into bexsero nimenrix, trumenba, menactra, Menveo, and other brands. The bexsero segment led the global market in 2022, with a market size of USD 1.2 billion. It is specifically developed to target meningococcal serotype B, which accounts for a significant proportion of meningococcal disease cases in certain regions. Serotype B is known for its antigenic diversity and its similarity to human tissues, making vaccine development complex. Bexsero's ability to target this challenging serotype has positioned it as a unique and valuable option for preventing serotype B-related disease. Moreover, it is often recommended for high-risk populations, such as adolescents and young adults, who are at increased risk of serogroup B meningococcal disease.
 

Based on the serotype, the meningococcal vaccines market is fragmented into serotype A, serotype B, serotype C, serotype W-135, and serotype Y. The serotype B segment is expected to reach USD 2.9 billion by 2032 growing at a CAGR of 7.2%. Serotype B has been associated with both sporadic cases and outbreaks, including those occurring in educational institutes such as colleges and universities. For instance, according to Centers for Disease Control and Prevention, Serotype B currently accounts for about 40% of cases in the U.S., with serogroups C, W and Y, as well as infections due to nongroupable (non-encapsulate) meningococci each causing a smaller proportion of cases overall. Such high number of cases due to serotype B, thus aids in high segmental growth.
 

Based on the age group, the meningococcal vaccines market is divided into infant (0 to 2 years), children and teen (2 to 18 years), and adult (18 years and above). The children and teen segment held high market share of 57.9% in 2022 and is expected to show significant growth at a CAGR of 6.8% during the analysis period. As children and teenagers are more susceptible to meningococcal disease as their developing immune systems and increased social interactions in school and community contributes to higher disease transmission rates. Close contact and shared living spaces in these environments can lead to outbreaks, making vaccination a priority. Furthermore, many meningococcal vaccines are administered as part of routine childhood immunization visits, making it convenient for parents to have their children vaccinated during scheduled healthcare appointments. Also, in some regions, certain meningococcal vaccines may be required for school entry. This requirement ensures that a large proportion of children and teenagers receive the vaccine, further driving demand within this age segment.
 

Based on the distribution channel, the meningococcal vaccines market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment led the global market in 2022, with a market size of USD 1.7 billion. Hospital pharmacies play a key role in the global market, as they are integral to the distribution, organisation, and administration of the vaccine within the healthcare ecosystem. The diverse patient base in hospital settings increases the likelihood of meningococcal vaccination being offered to various age groups. In addition, many hospitals offer vaccination services, including routine childhood and adolescent immunizations. This availability of vaccines as part of routine healthcare services contributes to hospital pharmacies being primary distribution channels for meningococcal vaccines.
 

 In 2022, the North American meningococcal vaccines market held the largest share of 57% and is anticipated to show considerable growth during the analysis period. The market is being driven by favourable initiatives and aids from governments as well as significant research & development expenditures in the region. A strong healthcare system and an increase in awareness campaigns in the area has fuelled market expansion. In addition, market players are also actively engaged in a public awareness drive to improve the region’s uptake of the meningococcal vaccination. For instance, in August 2021, GSK plc. Launched the ASK2Bsure campaign to entice parents to consult physicians about vaccinating their kids against meningitis B. This heightened disease awareness encourages individuals and healthcare providers to prioritize vaccination. Additionally, the region’s prominence on patient-focused care, along with the availability of vaccines, specialized medical centers and awareness, further drives the demand for meningococcal vaccines industry in the region.